Salud financiera de hoja de balance de Jagsonpal Pharmaceuticals
Salud financiera controles de criterios 6/6
Jagsonpal Pharmaceuticals has a total shareholder equity of ₹2.0B and total debt of ₹0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₹2.6B and ₹611.0M respectively. Jagsonpal Pharmaceuticals's EBIT is ₹226.5M making its interest coverage ratio -2.9. It has cash and short-term investments of ₹778.5M.
Información clave
0%
Ratio deuda-patrimonio
₹0
Deuda
| Ratio de cobertura de intereses | -2.9x |
| Efectivo | ₹778.45m |
| Patrimonio | ₹1.97b |
| Total pasivo | ₹610.95m |
| Activos totales | ₹2.58b |
Actualizaciones recientes sobre salud financiera
No hay actualizaciones
Recent updates
Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E
Oct 14
There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings
May 27There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump
Apr 30A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Apr 05Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking
Feb 06Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jul 29A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
May 13Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?
Jul 05A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jun 13Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting
Apr 19Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?
Mar 21Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?
Feb 08The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio
Jan 08Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock
Dec 21Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 30Análisis de la situación financiera
Pasivos a corto plazo: JAGSNPHARM's short term assets (₹1.4B) exceed its short term liabilities (₹469.9M).
Pasivo a largo plazo: JAGSNPHARM's short term assets (₹1.4B) exceed its long term liabilities (₹141.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: JAGSNPHARM is debt free.
Reducción de la deuda: JAGSNPHARM has no debt compared to 5 years ago when its debt to equity ratio was 4.1%.
Cobertura de la deuda: JAGSNPHARM has no debt, therefore it does not need to be covered by operating cash flow.
Cobertura de intereses: JAGSNPHARM has no debt, therefore coverage of interest payments is not a concern.